Urovant Sciences, Inc.
5281 California Avenue
About Urovant Sciences, Inc.
Urovant Sciences is a clinical-stage global biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant is a fast moving company with an entrepreneurial focus on improving the way and working on new therapies for patients affected by urologic conditions and their health care providers to treat and manage urologic diseases.
Every employee at Urovant plays an integral role to our success. We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve. Our fast-paced environment recognizes results, strategic decision-making and collaboration, giving team members opportunities to grow in this fast-moving company.
Urovant's lead product candidate, vibegron, is a β3-adrenergic agonist being developed for an oral, once-daily treatment for overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Urovant's second investigational product candidate, hMaxi-K, is a novel gene therapy for patients with overactive bladder (OAB) who have failed oral pharmacologic therapy. Urovant holds world-wide rights to this novel gene therapy.
Overactive bladder is a clinical condition characterized by the sudden urge to urinate, with or without accidental urinary leakage, and usually with increased urinary frequency. . In the United States, more than 30 million people over the age of 40 suffer from the bothersome symptoms of OAB1, which can lead to depression and anxiety and have a negative impact on quality of life.2
1. Coyne, et al., EpiLUTS 2007
2. Kinsey D, et al., J Health Psychol. 2016
Stock Symbol: UROV
Stock Exchange: NASDAQ